ArticleJournal of the American Heart Association2022
Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study.
Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 53 citations in OpenAlex.
- Effect of an intensive lifestyle intervention on cystatin C-based kidney function in adults with overweight and obesity: From the PREDIMED-Plus trial.Journal of internal medicine · 2025Trial
- Challenges of Biomarker Application in Patients with Cardiorenal Syndrome.Biomedicines · 2026Review
- Estimated glomerular filtration rate discordance and cardiopulmonary morbidity in sickle cell disease.Blood advances · 2026Article
- Social Isolation Trajectories Spanning Childhood to Adulthood and Mortality Risk in CKM Syndrome: Evidence From CHARLS.Brain and behavior · 2026Article
- Oxidative Stress-Driven Mechanisms and Biomarkers of Drug-Induced Nephrotoxicity: Translational Insights and Therapeutic Implications.Antioxidants (Basel, Switzerland) · 2026Review
- Imaging-based organ-specific aging clock predicts human diseases and mortality.NPJ digital medicine · 2026Article
- Predictive value of non-fasting apolipoprotein B/apolipoprotein A-1 ratio combined with systatin C for severe coronary artery stenosis in patients who undergo coronary angiography.Journal of cardiothoracic surgery · 2026Article
- Increased Urinary Albumin Excretion But Less Damaged Renal Tubular Structures in Mice with Genetically DecreasedInnovation discovery · 2026Article
- An interpretable machine learning model for predicting 1-year major adverse cardiovascular events in patients with type 2 diabetes and hypertension.Frontiers in medicine · 2026Article
- Heart Failure Biomarkers-Pathophysiology, Diagnosis, Prognosis and Clinical Relevance.International journal of molecular sciences · 2025Review
- Association of Osteopontin and selective glomerular hypofiltration syndrome with hospitalization for kidney failure in acute heart failure patients.BMC nephrology · 2025Article
- Integrating Novel Biomarkers into Clinical Practice: A Practical Framework for Diagnosis and Management of Cardiorenal Syndrome.Life (Basel, Switzerland) · 2025Review
- Novel eGFR equations and cardiovascular outcomes in a multiethnic Asian cohort.Clinical kidney journal · 2025Article
- Association of Serum Cystatin C with Stroke Morbidity and All-Cause and Cardio-Cerebrovascular Mortality: Evidence from the NHANES.Healthcare (Basel, Switzerland) · 2025Article
- The association between cystatin C and hypertension risk in diabetes patients: A multi-cohort cross-sectional study.iScience · 2025Article
- Current and novel biomarkers in cardiogenic shock.European journal of heart failure · 2025Review
- Infective endocarditis risk scores: a narrative review.Journal of thoracic disease · 2025Review
- Association between serum cystatin C and chronic lung disease in middle-aged and elderly Chinese: a CHARLS cross-sectional study.Scientific reports · 2025Article
- Adiponectin and TNF-Alpha Differentially Mediate the Association Between Cystatin C and Oxidized LDL in Type 2 Diabetes Mellitus Patients.International journal of molecular sciences · 2025Article
- Blood Biomarkers as a Non-Invasive Method for the Assessment of the State of the Fontan Circulation.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Elevated plasma cystatin C levels reflect reduced renal function and increased cardiovascular risk. Less is known about whether the increased risk persists long-term or is independent of renal function and other important biomarkers. Methods and Results Cystatin C and other biomarkers were measured at baseline (in 7863 patients) and 1 year later (in 6106 patients) in participants in the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study, who had a previous acute coronary syndrome. Outcomes were ascertained during the study (median follow-up, 6 years) and long-term (median follow-up, 16 years). Glomerular filtration rate (GFR) was estimated using Chronic Kidney Disease Epidemiology Collaboration equations (first GFR-creatinine, then GFR-creatinine-cystatin C). Over 6 years, in fully adjusted multivariable time-to-event models, with respect to the primary end point of coronary heart disease mortality or nonfatal myocardial infarction, for comparison of Quartile 4 versus 1 of baseline cystatin C, the hazard ratio was 1.37 (95% CI, 1.07-1.74;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.